RXi Pharma and Karolinska Institutet announce collaboration to develop sd-rxRNA compounds
RXi Pharmaceuticals announced a research collaboration with the Karolinska Institutet in Stockholm, Sweden. This collaboration will explore RXi's sd-rxRNA compounds against targets involved in T cell and NK cell differentiation and/or in the immune cell tumor-induced stress response. August 15, 2018